ADXN logoADXN
Addex Therapeutics Ltd - ADR

2,620
Loading...
Loading...
News
all
press releases
Crude Oil Dips; Addex Therapeutics Shares Spike Higher
read more...
Benzinga·1y ago
News Placeholder
More News
News Placeholder
Earnings Scheduled For April 18, 2024
Companies Reporting Before The Bell Addex Therapeutics (NASDAQ:ADXN) is estimated to report earnings for its fourth quarter. read more...
Benzinga·1y ago
News Placeholder
Addex Launches Neurosterix with $63M for Neurological R&D
Addex Therapeutics Ltd (CH:ADXN) has released an update. Addex Therapeutics has partnered with investment firm Perceptive Advisors to launch Neuros...
TipRanks Financial Blog·1y ago
News Placeholder
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
Addex receives CHF5M and 20% share of Neurosterix Perceptive Advisors leads $63M investment into Neurosterix Addex contributes portfolio of preclinical neuroscience assets and...
Globe Newswire·1y ago
News Placeholder
Addex Therapeutics Ltd (NASDAQ:ADXN) Short Interest Up 41.7% in March
Addex Therapeutics Ltd (NASDAQ:ADXN - Get Free Report) was the recipient of a significant growth in short interest in March. As of March 15th, there was short interest totalling 11,900 shares, a...
Ticker Report·1y ago
News Placeholder
Addex Therapeutics Ltd (NASDAQ:ADXN) Short Interest Update
Addex Therapeutics Ltd (NASDAQ:ADXN Get Free Report) was the target of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling...
Ticker Report·2y ago
News Placeholder
Addex to Present at the Swiss Equities Baader Conference
Geneva, Switzerland, January 9, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today...
Globe Newswire·2y ago
News Placeholder
Addex to Present at Biotech Showcase 2024
CEO to provide update on allosteric modulator pipeline clinical and preclinical development Geneva, Switzerland, January 5, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage...
Globe Newswire·2y ago

Latest ADXN News

View

Advertisement. Remove ads.

Advertisement. Remove ads.